Watson Launch Generic Dronabinol

Watson have announced the launch of generic dronabinol under a supply agreement with Solvay Pharmaceuticals.

Novartis initiate Clinical Trial Oral Parathyroid Hormone (PTH)

Novartis have initiated a Phase I of Oral Parathyroid Hormone (PTH) in postmenopausal women.The oral formulation was created using Emisphere’s proprietary Eligen technology.

United Therapeutics submit Treprostinil NDA for pulmonary arterial hypertension (PAH)

United Therapeutics have submitted a NDA to the U.S. FDA the approval of an inhaled formulation of treprostinil in the treatment of pulmonary arterial hypertension (PAH)

Bosentan receives positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension

Actelion have announced that Bosentan (Tracleer) has received a positive EU opinion for treatment of patients with mildly symptomatic WHO Functional Class II pulmonary arterial hypertension (PAH)

MAPS dihydroergotamine MAP0004 demonstrates preclincal activity

Data presented at the American Headache Society meeting shows that MAP Pharmaceutical’s inhaled dihydroergotamine MAP0004 stimulated receptors known to relieve migraine without activating receptors associated with side effects